表紙
市場調査レポート

前立腺肥大症:パイプライン製品の分析

Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232805
出版日 ページ情報 英文 128 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
前立腺肥大症:パイプライン製品の分析 Benign Prostatic Hyperplasia - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 128 Pages
概要

前立腺肥大症(BPH)は、男性の尿道を取り囲む小腺で精液の一部を作る前立腺の非癌性肥大であり、尿勢低下、 排尿後の尿滴下、排尿痛、夜間頻尿、腹圧排尿などの症状があります。BPHの治療には、手術や投薬などがあります。

当レポートでは、世界における前立腺肥大症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

前立腺肥大症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

前立腺肥大症:企業で開発中の治療薬

前立腺肥大症:大学/機関で研究中の治療薬

前立腺肥大症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

前立腺肥大症:企業で開発中の製品

前立腺肥大症:大学/機関で研究中の製品

前立腺肥大症の治療薬開発に従事している企業

  • AndroScience Corporation
  • Aphios Corporation
  • Ausio Pharmaceuticals, LLC
  • BCWorld Pharm Co. Ltd.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dongkook Pharmaceutical Co., Ltd.
  • Euroscreen S.A.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Jeil Pharmaceutical Co., Ltd.
  • 科研製薬
  • Meiji Seika Pharma Co., Ltd.
  • Mezzion Pharma Co. Ltd.
  • Monosol Rx, LLC
  • Nymox Pharmaceutical Corporation
  • Ono Pharmaceutical Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • SK Chemicals Co., Ltd.
  • SOM Innovation Biotech SL
  • Sophiris Bio, Inc.
  • Yungjin Pharm. Co., Ltd.

前立腺肥大症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

前立腺肥大症:最近のパイプライン動向

前立腺肥大症:休止中のプロジェクト

前立腺肥大症:開発が中止された製品

前立腺肥大症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8026IDB

Summary

Global Markets Direct's, 'Benign Prostatic Hyperplasia - Pipeline Review, H1 2016', provides an overview of the Benign Prostatic Hyperplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia
  • The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects
  • The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Benign Prostatic Hyperplasia Overview
    • Therapeutics Development
  • Pipeline Products for Benign Prostatic Hyperplasia - Overview
  • Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis
  • Benign Prostatic Hyperplasia - Therapeutics under Development by Companies
  • Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes
  • Benign Prostatic Hyperplasia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Benign Prostatic Hyperplasia - Products under Development by Companies
  • Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes
  • Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
    • AndroScience Corporation
    • Aphios Corporation
    • Ausio Pharmaceuticals, LLC
    • BCWorld Pharm Co. Ltd.
    • Chong Kun Dang Pharmaceutical Corp.
    • Dongkook Pharmaceutical Co., Ltd.
    • Euroscreen S.A.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Jeil Pharmaceutical Co., Ltd.
    • Kaken Pharmaceutical Co., Ltd.
    • Meiji Seika Pharma Co., Ltd.
    • Mezzion Pharma Co. Ltd.
    • Monosol Rx, LLC
    • Nymox Pharmaceutical Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • SK Chemicals Co., Ltd.
    • SOM Innovation Biotech SL
    • Sophiris Bio, Inc.
    • Yungjin Pharm. Co., Ltd.
  • Benign Prostatic Hyperplasia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dutasteride + tadalafil) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (tadalafil + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASC-JM.X2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AUS-131 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BCWPE-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-214 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CKD-902 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ESN-364 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fadanafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fexapotide triflutate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1303 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HIP-1402 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • L-1AD3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCS-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NCE-403 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONO-8430506 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-40542 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-052 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SOM-2391 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SOM-2393 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Sperol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • talaporfin sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tamsulosin hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tamsulosin hydrochloride DR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tertomotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • topsalysin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YBH-1603 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YOB-1604 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Benign Prostatic Hyperplasia - Recent Pipeline Updates
  • Benign Prostatic Hyperplasia - Dormant Projects
  • Benign Prostatic Hyperplasia - Discontinued Products
  • Benign Prostatic Hyperplasia - Product Development Milestones
    • Featured News & Press Releases
      • May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting
      • Apr 01, 2015: Nymox Announces Phase 3 BPH Studies
      • Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
      • Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints
      • Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
      • Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
      • Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
      • Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
      • Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
      • May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016
  • Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Ausio Pharmaceuticals, LLC, H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Euroscreen S.A., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Monosol Rx, LLC, H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by SOM Innovation Biotech SL, H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H1 2016
  • Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H1 2016
  • Benign Prostatic Hyperplasia - Dormant Projects, H1 2016
  • Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H1 2016
  • Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H1 2016
  • Benign Prostatic Hyperplasia - Dormant Projects (Contd..3), H1 2016
  • Benign Prostatic Hyperplasia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016
  • Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top